TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Corbus Pharmaceuticals Announces Pricing of Public Offering

Benzinga Logo Benzinga By Globe Newswire
Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals has priced a public offering of 4,744,231 common stock shares and pre-funded warrants, raising approximately $75 million to fund clinical development and corporate purposes.

Insights
GSpC   neutral

Mentioned as Crowder's former employer, no specific positive or negative context


CRBP   neutral

The company is raising capital through a standard public offering to fund ongoing research and development, indicating a strategic financial move without strong positive or negative implications